ClinTec’s CEO Wins the Institute of Directors, Director of the Year Award for Glasgow & West of Scotland
News Mar 23, 2010
Dr Rabinder Buttar, President & CEO of Global CRO (Contract Research Organization), ClinTec International, became the only female director this year to pick up a Regional Director’s Award at the renowned Institute of Directors (IOD), Director of the Year Awards.
Dr Buttar picked up the Regional Award for Glasgow & West of Scotland during the exclusive event held at Edinburgh’s Grand Sheraton Hotel and attended by over 300 guests. Kaye Adams, journalist and former lead presenter of Loose Women, and John Swinney, MSP for North Tayside and Cabinet Secretary for Finance and Sustainable Growth in the Scottish Government, presented the prestigious awards ceremony.
The IOD Awards celebrate the successes of Scotland’s business leaders and acknowledge the vision and courage the directors have shown in 2009 to drive their organisations forward in a challenging climate.
Dr Buttar was overjoyed to reach the finals for two awards: Global Business Director of the Year and West of Scotland Regional Director.
On receiving the award, Dr Buttar commented: “I am truly honoured to become the IoD’s Director of the Year for Glasgow & West of Scotland. I would like to accept this award on behalf of ClinTec’s Glasgow HQ and global teams, who have been essential in helping ClinTec get to where it is today.”
She continued, “2009 was our most successful year yet, which I believe is all down to my staff’s loyalty and can-do attitude, supporting our clients’ needs in the every way possible. My thanks also go to all our business and co-operation partners in the West of Scotland who have been truly excellent in supporting us through this immense period of growth.”
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE